“While the phase 3 results of GCAptAIN did not replicate the positive outcomes observed in the phase 2 trial, we remain committed to continuing to drive scientific progress and deepening the ...

Both regulatory-approved and pipeline treatments for moderate to severe hidradenitis suppurativa demonstrate comparable ...

Novartis announced top-line results from the phase III GCAptAIN study evaluating Cosentyx (secukinumab) in adults with newly diagnosed or relapsing giant cell arteritis (GCA). In the study, Cosentyx ...

SAN DIEGO — An intravenous formulation of secukinumab met all primary efficacy endpoints, with an attractive safety profile, in patients with axial spondyloarthritis over 52 weeks, according to ...

Basel, November 15, 2014 - Novartis announced today results from the MEASURE 1 and MEASURE 2 pivotal Phase III studies of AIN457 (secukinumab) in ankylosing spondylitis (AS).In the studies ...

BOSTON — The human monoclonal antibody secukinumab (Novartis), which selectively neutralizes interleukin (IL)-17A, is safe and effective for patients with ankylosing spondylitis and psoriatic ...

Compared with placebo, secukinumab demonstrated superior pain reduction in moderate to severe hidradenitis suppurativa in two phase 3 trials. Improvements in pain were sustained through week 52 ...

Secukinumab, an anti-IL-17A monoclonal antibody biologic drug, showed promise as a treatment for patients with active ankylosing spondylitis, according to new research. Ankylosing spondylitis, or ...

Both secukinumab 300 mg (28.2%) and 150 mg (24.3%) also led to higher ACR50 response rates at week 16 compared with placebo (5.8%), both with significant ORs.

Secukinumab demonstrated rapid, stained improvements in fatigue for up to 3 years among patients with ankylosing spondylitis, according to data published in Arthritis Care & Research. &ldquo ...

Patients randomized to secukinumab after 12 weeks following a 12-week open label period had a significantly longer time to flare and a 72% reduction in risk of flare compared with those given ...

Overview of the clinical trials . 3.1 The company did a systematic review of the literature to identify studies evaluating the clinical effectiveness and safety of secukinumab for treating people with ...